Valeo Pharma Inc. (OTCMKTS:VPHIF) Stock Continues to Trade in a Narrow Range
Shares of Valeo Pharma Inc. (OTCMKTS:VPHIF) have been trading within a narrow range over past few trading sessions.
Market Stats
On Wednesday, VPHIF stock ended lower by 0.67% to $0.5785 with more than 6.1K shares, compared to its average volume of 1.5k shares. The stock has moved within a range of $0.5785 – 0.5881 after opening trading at $0.5787.
Hesperco by Valeo Pharma on Sale at Loblaws; Clinical Trial Results of Hesperidin are Encouraging
Canadian pharmaceutical company, Valeo Pharma Inc. (OTCMKTS:VPHIF) announced on January 5, 2022, about Hesperco, its unique flavonoid formulation, approved by Health Canada for immune support, being available for sale.
The product can be found in around 300 stores under the Loblaw’s banners including Loblaws, Dominion, Zehrs, Fortinio’s, Your Independent Grocer and Superstore. Hesperidin, the active medicinal ingredient in Hesperco capsules, has excellent immune support properties, which is mentioned in several scientific publications.
Back in April 2020, Valeo had signed a collaboration and licensing agreement with Ingenew Pharma Inc. for developing, manufacturing, and commercializing Hesperco. The latter has developed proprietary knowhow regarding the use of Hesperidin to treat infections resulting due to contracting the Covid-19 virus. Ingenew has also collaborated with the Montreal Heart Institute for a randomized, double-blind, placebo controlled clinical trial.
Highlights from the study have been provided by Ingenew, about the effect of hesperidin on COVID-19 symptoms, in its December 22, 2021 press release. Mr. Pierre Laurin, MSc Pharm, President of Ingenew Pharma, stated that the study confirms safety of hesperidin and potential benefits for managing Covid-19 symptoms. The results look extremely promising. As of now, they are working on conducting follow-on studies regarding earlier treatment of longer duration and/or higher dosage.
Key Quote
“We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications”, said Steve Saviuk, CEO. “We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”
Traders Corner
VPHIF stock is trading below the 50-Day and 100-Day Moving averages of $0.6003 and $0.6134 respectively. The stock is trading in neutral zone with the RSI at 50.
